Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy

European Respiratory Review : an Official Journal of the European Respiratory Society
H Teschler

Abstract

Although it is often under-recognised, α1-antitrypsin deficiency (AATD) represents one of the most common genetic respiratory disorders worldwide. Since the publication of studies in the late 1980s, which demonstrated that plasma-derived augmentation therapy with intravenous α1-antitrypsin (AAT) can reverse the biochemical deficiencies in serum and lung fluid that characterise emphysema, augmentation therapy has become the cornerstone of patient management. This article, with a focus on experience gained in clinical practice in Germany, provides an overview of some of the research highlights and clinical experience gained in the use of augmentation therapy for AATD during the past 25 years, and briefly discusses the potential role of AAT augmentation therapy in lung transplant recipients. Additionally, the goals of AAT augmentation therapy will be discussed, namely to delay the progression of emphysema, reduce the frequency of exacerbations and improve health-related quality of life. Beyond pulmonary disease, there is recent growing evidence to indicate that AATD could also play a role in rare disorders such as panniculitis, granulomatosis with polyangiitis and ulcerative colitis.

References

Apr 23, 1987·The New England Journal of Medicine·M D WewersR G Crystal
Nov 11, 1999·American Journal of Respiratory and Critical Care Medicine·A DirksenJ Stolk
Mar 13, 2001·Chest·M WenckerUNKNOWN Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen
Oct 3, 2003·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN European Respiratory Society
Jun 28, 2005·Lancet·James K Stoller, Loutfi S Aboussouan
Oct 9, 2009·COPD·Kenneth R ChapmanRoberta J Navickis
Jul 28, 2010·Therapeutic Advances in Respiratory Disease·Thomas KöhnleinTobias Welte
Feb 23, 2012·Therapeutic Advances in Respiratory Disease·Juan Carlos Barros-TizónUNKNOWN Investigators of the rEXA study group
Mar 20, 2012·Thorax·Ilaria FerrarottiMaurizio Luisetti
Apr 17, 2012·Expert Opinion on Biological Therapy·Manish MohankaJames K Stoller
Jan 2, 2014·Trends in Molecular Medicine·Robert A Stockley, Alice M Turner

❮ Previous
Next ❯

Citations

Mar 12, 2016·Expert Opinion on Therapeutic Patents·Yotam LiorEli C Lewis
Mar 4, 2017·Current Opinion in Pulmonary Medicine·E F M WoutersF M E Franssen
Dec 9, 2016·Human Gene Therapy·Dolan SondhiRonald G Crystal
Sep 6, 2015·Therapeutic Advances in Respiratory Disease·Timm Greulich, Claus F Vogelmeier
Feb 24, 2018·British Journal of Pharmacology·David J WilkinsonAndrew D Rowan
Oct 31, 2017·Expert Review of Respiratory Medicine·Mario CazzolaMaria Gabriella Matera
Dec 2, 2017·The European Respiratory Journal·Ani Manichaikul, Jennifer N Nguyen
Oct 17, 2019·International Journal of Nursing Practice·Ayşegül Yayla, Nadiye Özer
Sep 6, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Simona ViglioJan Stolk
Jul 14, 2021·Current Opinion in Pharmacology·Katharina RemihPavel Strnad
Aug 20, 2021·Therapeutic Advances in Chronic Disease·Martin R Zamora, Ali Ataya

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.